Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.The pharmaceutical giant now projects 13.5billioninrevenueforthequarter,sparkingconcernsovertheperformanceofitsblockbusterweight−lossanddiabetesdrugs,MounjaroandZepbound.AsofthemarketcloseonJanuary14,EliLilly’sstockwastradingat744.91, reflecting a one-day loss of over 6.5%. On the five-d ...